Michael J Evans

List of Publications by Year
in descending order

66 papers	2,506 citations	236925 25 h-index	206112 48 g-index
71 all docs	71 docs citations	71 times ranked	4479 citing authors

#	Article	IF	Citations
1	Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology. Methods in Molecular Biology, 2022, 2393, 829-839.	0.9	0
2	In Vivo Profiling with ¹⁸F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. Molecular Pharmaceutics, 2022, 19, 704-709.	4.6	2
3	Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. Journal of Clinical Investigation, 2022, 132, .	8.2	13
4	Switchable assembly and function of antibody complexes inÂvivo using a small molecule. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	7
5	Ferrous ironâ€“activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. Journal of Experimental Medicine, 2022, 219, .	8.5	15
6	Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats. Journal of Nuclear Medicine, 2022, 63, 1259-1265.	5.0	11
7	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical Cancer Research, 2022, 28, 3066-3075.	7.0	10
8	Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies. Journal of Nuclear Medicine, 2021, 62, jnumed.120.252460.	5.0	21
9	Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clinical Cancer Research, 2021, 27, 1305-1315.	7.0	18
10	Synthesis and Screening of Î±-Xylosides in Human Glioblastoma Cells. Molecular Pharmaceutics, 2021, 18, 451-460.	4.6	5
11	The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (Â±)-¹¹C-YJH08 PET. Journal of Nuclear Medicine, 2021, 62, 723-731.	5.0	2
12	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. JAMA Network Open, 2021, 4, e2119400.	5.9	29
13	Epidemiology and treatment of BehÃ§etâ€™s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions. Arthritis Research and Therapy, 2021, 23, 224.	3.5	10
14	In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Central Science, 2021, 7, 1638-1649.	11.3	30
15	Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen. ACS Applied Materials & Interfaces, 2021, 13, 54739-54752.	8.0	9
16	The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatologyâ€™s Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study. JMIR Medical Informatics, 2021, 9, e31186.	2.6	4
17	Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Molecular Imaging and Biology, 2020, 22, 208-216.	2.6	16
18	Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. International Journal of Radiation Oncology Biology Physics, 2020, 108, 242-257.	0.8	8

#	Article	IF	Citations
19	An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Molecular Imaging and Biology, 2020, 22, 1553-1561.	2.6	11
20	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 3608-3615.	7.0	24
21	Arabinofuranoseâ€derived positronâ€emission tomography radiotracers for detection of pathogenic microorganisms. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 231-239.	1.0	5
22	A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chemical Biology, 2020, 15, 1381-1391.	3.4	4
23	Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Molecular and Cellular Proteomics, 2020, 19, 294-307.	3.8	8
24	AGuIX^{Â®} from bench to bedsideâ€"Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, 2019, 92, 20180365.	2.2	86
25	Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Molecular Pharmaceutics, 2019, 16, 3831-3841.	4.6	36
26	Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 348-357.	0.7	4
27	Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography. ACS Central Science, 2019, 5, 727-736.	11.3	38
28	A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 166-176.	7.0	14
29	Enzymatically Catalyzed Radiofluorination of Biomolecules. Methods in Molecular Biology, 2019, 2033, 191-205.	0.9	0
30	Development of a stress response therapy targeting aggressive prostate cancer. Science Translational Medicine, 2018, 10, .	12.4	124
31	Noninvasive ⁸⁹Zr-Transferrin PET Shows Improved Tumor Targeting Compared with ¹⁸F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. Journal of Nuclear Medicine, 2018, 59, 51-57.	5.0	31
32	Imaging PD-L1 Expression with ImmunoPET. Bioconjugate Chemistry, 2018, 29, 96-103.	3.6	109
33	A Preclinical Assessment of ⁸⁹Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with ⁸⁹Zr-C4. Bioconjugate Chemistry, 2018, 29, 3476-3482.	3.6	37
34	Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. ELife, 2018, 7, .	6.0	72
35	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2045-2054.	6.4	116
36	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. European Urology Oncology, 2018, 1, 78-82.	5.4	74

#	Article	IF	Citations
37	Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight, 2018, 3, .	5.0	26
38	Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. Journal of Clinical Investigation, 2018, 129, 349-363.	8.2	99
39	Measuring glucocorticoid receptor expressionin vivowith PET. Oncotarget, 2018, 9, 20399-20408.	1.8	8
40	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research, 2017, 15, 1221-1229.	3.4	27
41	Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. Clinical Cancer Research, 2017, 23, 3045-3052.	7.0	31
42	Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen. ACS Chemical Biology, 2017, 12, 2934-2939.	3.4	11
43	Imaging Hepatocellular Carcinoma With⁶⁸Ga-Citrate PET: First Clinical Experience. Molecular Imaging, 2017, 16, 153601211772325.	1.4	6
44	⁶⁸Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Journal of Nuclear Medicine, 2017, 58, 81-84.	5.0	166
45	Site-Specific Radiofluorination of Biomolecules with 8-[¹⁸F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chemical Biology, 2016, 11, 1587-1594.	3.4	18
46	A reactivity-based [¹⁸F]FDG probe for in vivo formaldehyde imaging using positron emission tomography. Chemical Science, 2016, 7, 5503-5507.	7.4	27
47	A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 946-951.	2.6	33
48	Synthesis and Characterization of ⁸⁹Zr-Labeled Ultrasmall Nanoparticles. Molecular Pharmaceutics, 2016, 13, 2596-2601.	4.6	24
49	Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Molecular Pharmaceutics, 2016, 13, 683-688.	4.6	12
50	Caged [¹⁸F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjugate Chemistry, 2016, 27, 170-178.	3.6	38
51	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. European Urology, 2015, 68, 1076-1082.	1.9	12
52	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Research, 2015, 75, 4688-4696.	0.9	105
53	Annotating STEAP1 Regulation in Prostate Cancer with 89Zr Immuno-PET. Journal of Nuclear Medicine, 2014, 55, 2045-2049.	5.0	25
54	Underscoring the Influence of Inorganic Chemistry on Nuclear Imaging with Radiometals. Inorganic Chemistry, 2014, 53, 1880-1899.	4.0	75

#	Article	IF	Citations
55	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes and Development, 2014, 28, 1800-1814.	5.9	167
56	The Basement Membrane Zone in Asthma: The Supracellular Anchoring Network. Current Respiratory Medicine Reviews, 2014, 9, 268-273.	0.2	0
57	Imaging Tumor Burden in the Brain with ⁸⁹Zr-Transferrin. Journal of Nuclear Medicine, 2013, 54, 90-95.	5.0	33
58	Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology. Journal of Nuclear Medicine, 2013, 54, 1876-1882.	5.0	58
59	Annotating MYC status with 89Zr-transferrin imaging. Nature Medicine, 2012, 18, 1586-1591.	30.7	83
60	Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer. Cancer Discovery, 2012, 2, 985-994.	9.4	16
61	Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9578-9582.	7.1	268
62	Fibroblast growth factor-2 during postnatal development of the tracheal basement membrane zone. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L1263-L1270.	2.9	34
63	Fibroblast Growth Factor-2 in Remodeling of the Developing Basement Membrane Zone in the Trachea of Infant Rhesus Monkeys Sensitized and Challenged with Allergen. Laboratory Investigation, 2002, 82, 1747-1754.	3.7	33
64	Three-Dimensional Organization of the Lamina Reticularis in the Rat Tracheal Basement Membrane Zone. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 393-397.	2.9	27
65	Junctional Adhesion Mechanisms in Airway Basal Cells. American Journal of Respiratory Cell and Molecular Biology, 1990, 3, 341-347.	2.9	38
66	Exploiting KRAS-Driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC). SSRN Electronic Journal, 0, , .	0.4	0